Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by Ingiboyon Feb 22, 2023 12:36pm
60 Views
Post# 35298613

RE:RE:RE:RE:Disappointing Day

RE:RE:RE:RE:Disappointing Day
BellEnd wrote: What kind of tangible things are possible, the DI is only suppose to be finished testing in a month from the meeting, arbitration is like may 28th for the hearing.
all other studies are pursuant to other money coming in from the DI or rch-01 settlement/movement.

probably going to be very lack lustre 


Not sure where you got your information regarding the Dermal Injector testing.  Regardless, the device is now at the commercial grade level.  No more adjustments to be made.  

I assume we will hear the timeline for the submission to the FDA.  Also questions will be asked at the meeting regarding which countries will be launching the device other than China/Hong Kong and the United States.  I assume it will also be launched in Japan.
Questions will also be asked regarding the Arbitration with Shiseido.  I am thinking that Replicel has recently been making overtures to Shiseido regarding various deal scenarios between the two companies.
This AGM will not be "lacklustre".

<< Previous
Bullboard Posts
Next >>